12:00 AM
 | 
Apr 01, 2013
 |  BC Week In Review  |  Company News  |  Deals

Arcion, BioDelivery deal

Arcion granted BioDelivery exclusive, worldwide rights to develop and commercialize topical clonidine gel (formerly ARC-4558). Arcion will receive $2 million in BioDelivery common stock up front and is eligible to receive $2.5 million in stock...

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >